nVerses Capital LLC Has $62,000 Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

nVerses Capital LLC reduced its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 77.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 500 shares of the biotechnology company’s stock after selling 1,700 shares during the quarter. nVerses Capital LLC’s holdings in Sarepta Therapeutics were worth $62,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Innealta Capital LLC bought a new stake in Sarepta Therapeutics during the second quarter worth about $31,000. Mather Group LLC. bought a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $28,000. Riggs Asset Managment Co. Inc. boosted its position in shares of Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 125 shares in the last quarter. New Covenant Trust Company N.A. bought a new position in Sarepta Therapeutics in the first quarter valued at approximately $32,000. Finally, Nkcfo LLC acquired a new position in Sarepta Therapeutics during the second quarter valued at approximately $43,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Up 0.2 %

Sarepta Therapeutics stock opened at $127.31 on Tuesday. The firm has a market cap of $12.03 billion, a price-to-earnings ratio of 1,157.36 and a beta of 0.82. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90. The firm has a 50 day moving average price of $129.00 and a two-hundred day moving average price of $132.39.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. Sarepta Therapeutics’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.27) earnings per share. Equities analysts predict that Sarepta Therapeutics, Inc. will post 1.45 EPS for the current year.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Michael Andrew Chambers bought 37,038 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the transaction, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Michael Andrew Chambers bought 37,038 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on SRPT shares. Jefferies Financial Group started coverage on Sarepta Therapeutics in a report on Monday. They issued a “buy” rating and a $165.00 target price on the stock. Evercore ISI upgraded Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and decreased their target price for the company from $185.00 to $179.00 in a research report on Thursday, August 8th. Barclays dropped their target price on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Citigroup decreased their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Finally, BMO Capital Markets raised their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. Two analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average target price of $182.95.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.